A positive test result for COVID-19 indicates that RNA from SARS-CoV-2 was detected, and the patient is infected with the virus and presumed to be contagious. Laboratory test results should always be considered in the context of clinical observations and epidemiological data in making a final diagnosis and patient management decisions. Patient management should follow current CDC guidelines.
The Rutgers Clinical Genomics Laboratory TaqPath SARS-CoV-2 Assay has been designed to minimize the likelihood of false-positive test results. However, in the event of a false-positive result, risks to patients could include the following: a recommendation for isolation of the patient, monitoring of household or other close contacts for symptoms, patient isolation that might limit contact with family or friends and may increase contact with other potentially COVID-19 patients, limits in the ability to work, the delayed diagnosis and treatment for the true infection causing the symptoms, unnecessary prescription of treatment or therapy, or other unintended adverse effects.
All laboratories using this test must follow the standard testing and reporting guidelines according to their appropriate public health authorities.